These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31986515)

  • 1. A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial).
    Okuyama H; Ikeda M; Okusaka T; Furukawa M; Ohkawa S; Hosokawa A; Kojima Y; Hara H; Murohisa G; Shioji K; Asagi A; Mizuno N; Kojima M; Yamanaka T; Furuse J
    Neuroendocrinology; 2020; 110(11-12):988-993. PubMed ID: 31986515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma.
    Ikeda M; Okuyama H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Kondo S; Morizane C; Ueno H; Okusaka T
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):623-7. PubMed ID: 25755102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus in Pancreatic Neuroendocrine Carcinomas G3.
    Panzuto F; Rinzivillo M; Spada F; Antonuzzo L; Ibrahim T; Campana D; Fazio N; Delle Fave G
    Pancreas; 2017 Mar; 46(3):302-305. PubMed ID: 28099254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
    Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R
    Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea.
    Lee KJ; Cho JH; Lee SH; Song SY; Lee KH; Jeong S; Ryu JK; Woo SM; Bang S; Lee JK; Lee TH; Paik WH; Kim YT; Lee WJ
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):799-805. PubMed ID: 28884280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
    Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
    Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.
    Staehler M; Stöckle M; Christoph DC; Stenzl A; Potthoff K; Grimm MO; Klein D; Harde J; Brüning F; Goebell PJ; Augustin M; Roos F; Benz-Rüd I; Marschner N; Grünwald V
    Int J Cancer; 2021 Apr; 148(7):1685-1694. PubMed ID: 33070307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.
    Schneider TC; de Wit D; Links TP; van Erp NP; van der Hoeven JJ; Gelderblom H; Roozen IC; Bos M; Corver WE; van Wezel T; Smit JW; Morreau H; Guchelaar HJ; Kapiteijn E
    J Clin Endocrinol Metab; 2017 Feb; 102(2):698-707. PubMed ID: 27870581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).
    Vernieri C; Pusceddu S; Fucà G; Indelicato P; Centonze G; Castagnoli L; Ferrari E; Ajazi A; Pupa S; Casola S; Foiani M; Mazzaferro V; Pruneri G; Milione M; de Braud F
    Int J Cancer; 2019 Apr; 144(7):1704-1712. PubMed ID: 30520016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.
    Fazio N; Buzzoni R; Delle Fave G; Tesselaar ME; Wolin E; Van Cutsem E; Tomassetti P; Strosberg J; Voi M; Bubuteishvili-Pacaud L; Ridolfi A; Herbst F; Tomasek J; Singh S; Pavel M; Kulke MH; Valle JW; Yao JC
    Cancer Sci; 2018 Jan; 109(1):174-181. PubMed ID: 29055056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amrubicin Monotherapy for Patients with Platinum-Pretreated Non-Gastrointestinal Non-Pancreatic Extrapulmonary Neuroendocrine Carcinoma.
    Ebata T; Shimoi T; Ishiwata T; Iwasawa S; Bun S; Yunokawa M; Yonemori K; Takiguchi Y; Tamura K
    Oncology; 2017; 93(3):177-182. PubMed ID: 28521313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
    Zucali PA; De Pas T; Palmieri G; Favaretto A; Chella A; Tiseo M; Caruso M; Simonelli M; Perrino M; De Vincenzo F; Toffalorio F; Damiano V; Pasello G; Garbella E; Ali M; Conforti F; Ottaviano M; Cioffi A; De Placido S; Giordano L; Bertossi M; Destro A; Di Tommaso L; Santoro A
    J Clin Oncol; 2018 Feb; 36(4):342-349. PubMed ID: 29240542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study.
    Gerard L; Garcia J; Gauthier A; Lopez J; Durand A; Hervieu V; Lemelin A; Chardon L; Landel V; Gibert B; Lombard-Bohas C; Payen L; Walter T
    Neuroendocrinology; 2021; 111(10):951-964. PubMed ID: 33099543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09).
    Niegisch G; Retz M; Thalgott M; Balabanov S; Honecker F; Ohlmann CH; Stöckle M; Bögemann M; Vom Dorp F; Gschwend J; Hartmann A; Ohmann C; Albers P
    Oncology; 2015; 89(2):70-8. PubMed ID: 25765871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma.
    Kobayashi N; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Hiroshima Y; Ichikawa Y
    Cancer Sci; 2021 May; 112(5):1936-1942. PubMed ID: 33453146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.
    Yao JC; Pavel M; Lombard-Bohas C; Van Cutsem E; Voi M; Brandt U; He W; Chen D; Capdevila J; de Vries EGE; Tomassetti P; Hobday T; Pommier R; Öberg K
    J Clin Oncol; 2016 Nov; 34(32):3906-3913. PubMed ID: 27621394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial).
    Ramage JK; Punia P; Faluyi O; Frilling A; Meyer T; Saharan R; Valle JW
    Neuroendocrinology; 2019; 108(4):317-327. PubMed ID: 30699423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
    Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
    Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.